Adding Herceptin medicines to chemo for HER2-positive endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 3 trial tests whether adding Herceptin Hylecta or Phesgo to standard chemotherapy works better than chemotherapy alone for HER2-positive serous endometrial cancer or carcinosarcoma. It may help by improving how well treatment controls or shrinks the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive endometrial cancer (serous, other endometrial types, or carcinosarcoma), and it is not mismatch repair deficient (dMMR)
- Your cancer was confirmed by a pathology report (surgery or biopsy), and you received that diagnosis as the original tumor
- You are starting treatment within 8 weeks after your main surgery (or biopsy if you didn’t have surgery), and the cancer is not back yet
- Your tumor has to be HER2-positive by local lab testing (IHC/ISH or approved genetic testing showing HER2 amplification), and the results must be submitted
- You are well enough to tolerate treatment (ECOG 0–2) and meet basic blood and organ health test limits (kidney, liver, blood counts)
- You must not have had prior chemotherapy/targeted therapy/biologic therapy or radiation for this endometrial cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial compares a new targeted medicine (trastuzumab deruxtecan) against standard chemotherapy for women with a certain type of advanced endometrial cancer that has high levels of HER2 protein. It's for people whose cancer is newly diagnosed and has spread to nearby tissues but not to distant organs.
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This study tests whether adding surgery to remove the breast tumor and radiation therapy to destroy remaining cancer spots improves outcomes for people diagnosed with HER2-positive breast cancer that has already spread to a few other parts of the body. You'll receive standard chemotherapy and HER2-targeted drugs first, then be assigned to receive either additional surgery and radiation or to continue with standard care.
Hear when a new Endometrial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.